A very powerful GIP/GLP-1 co-agonist, tirzepatide is currently under clinical development; this compound results in large weight losses in people with diabetes (54) and losses exceeding 20% in people with obesity (Lilly, press release May 2022). The gene discussed is GCG; the disease is obesity due to melanocortin 4 receptor deficiency.